Negative Patient Care Perceptions Linked to Increased Number of Pre-diagnostic Consultations
the Cancer Therapy Advisor take:
There is a negative association between multiple pre-referral consultations with a general practitioner and the patient experience of subsequent cancer care, according to an article published online in the European Journal of Cancer Care.
The study included data from 73,462 respondents to two English Cancer Patient Experience Surveys. The authors evaluated the likelihood of patients reporting negative experiences of subsequent care after three or more (3+) pre-referral consultations compared to one or two consultations.
Results showed a strong correlation (P<0.01 for all) between patients with 3+ pre-referral consultations and perceived worse care experiences (for 10/12 questions), compared to those with 1-2 consultations ranging from 1.10 to 1.68 (95% CI: 1.03, 1.17 vs. 1.60-1.77, respectively).
In other words, patients with 3+ consultations had a +1.8% to +10.6% greater percentage of reporting a negative subsequent care experience than those with 1-2 visits.
The associations were reported to be stronger when related to primary care as opposed to hospital care, and for evaluation than report items.
Furthermore, a “dose-response” relationship was found after considering 1, 2, 3-4, and 5+ pre-referral consultations separately.
There is a negative association between multiple pre-referral consultations with a general practitioner and the patient experience.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Arrival of CAR-T Immunotherapy Raise Hopes for Treatment and Anxieties About Costs
- St John's Wort and Cancer
- Osimertinib Granted Breakthrough Therapy Designation as First-line Treatment for EGFR-positive NSCLC
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?
- NSCLC: Researchers Identify Socioeconomic Factors Linked to Overall Survival
- Savolitinib Plus Gefitinib May Be Effective in EGFR-Mutant, MET-amplified NSCLC
- Maintenance Pazopanib Provides PFS, not OS, Benefit in Small-cell Lung Cancer
- Pembrolizumab Plus Pemetrexed, Carboplatin Prolongs Survival in NSCLC
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC